Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
38 hedge funds and large institutions have $6.85M invested in Biolase, Inc. in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 11 closing their positions.
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
52% less capital invested
Capital invested by funds: $14.4M → $6.85M (-$7.56M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$395K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$40.4K |
| 3 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$30.3K |
| 4 |
HF
HRT Financial
New York
|
+$26.5K |
| 5 |
ZF
Zhang Financial
Portage,
Michigan
|
+$22.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$802K |
| 2 |
Millennium Management
New York
|
-$737K |
| 3 |
Renaissance Technologies
New York
|
-$720K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$343K |
| 5 |
Two Sigma Advisers
New York
|
-$248K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | -$2K | -1 | Closed |
|
52
1832 Asset Management
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
BIOL Hedge Fund Activity: Q4 2021 in Review
38 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2021, worth a combined $6.85M — down 52% from $14.4M a quarter earlier.
Fund positioning in BIOL was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 4 added to existing stakes and 11 trimmed.
The largest buyer was Essex Investment Management, adding an estimated $395K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $802K sold.
- 38 institutional investors held Biolase, Inc. (BIOL) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $6.85M of Biolase, Inc. stock for Q4 2021, down 52% quarter-over-quarter.
- 11 funds opened new Biolase, Inc. positions in Q4 2021 and 11 closed out, a net change of 0 holders.
- The largest Biolase, Inc. buyer in Q4 2021 was Essex Investment Management, an estimated $395K added.
- The largest Biolase, Inc. seller in Q4 2021 was GSA Capital Partners, an estimated $802K sold.
Based on aggregated 13F filings for Q4 2021.